Last, we evaluated MEIS2 as a novel putative druggable target in neuroblastoma by exposing IMR32, N206 (Kelly) and SK-N-BE(2)-C neuroblastoma cells to a range of concentrations of a recently developed inhibitor Meisi-2 (Meinox Pharma Technologies, Istanbul, Turkey), targeting both MEIS1 and MEIS2 and recently described to modulate hematopoietic stem cell activity [30]. This evidence concerns the gene MEIS1 and neuroblastoma.